<p>A very rare, severe genetic condition known as fibrodysplasia ossificans progressiva (FOP) is characterized by progressive heterotopic ossification of soft tissues caused on by mutations in the ACVR1 gene, particularly R206H, which results in abnormal BMP signalling. This condition causes severe mobility limitations and life-threatening complications. The goal of this review is to thoroughly examine current developments in stem cell, pharmacologic, and genetic therapy for FOP and assess their potential for translation in clinical settings. Current understanding highlights that mutant ACVR1 receptors respond abnormally to Activin A, triggering pathological ossification. Innovations such as CRISPR-Cas9 gene editing, antisense oligonucleotides, and RNA interference show promise in correcting or silencing these mutations. Several Pharmacological advances include saracatinib (evaluated in Phase II studies), garetosmab (anti-Activin A antibody with early clinical data), and palovarotene which received FDA approval in August 2023 for reducing HO in FOP. Though post-marketing data highlight ongoing concerns regarding growth-plate toxicity and long-term skeletal safety. However, significant translational challenges persist, including limited long-term safety data, heterogeneous patient responses, and gaps between preclinical success and clinical efficacy. Stem cell therapies using MSCs and iPSCs offer regenerative potential and personalized modeling platforms. Smart drug delivery devices and precision medicine techniques guided by biomarkers improve therapy targeting and monitoring. Although there are still issues with delivery, safety, and long-term effectiveness, a mix of targeted medications, gene-based treatments, and cutting-edge technology is opening the door to precision and combination therapies, which provide patients with FOP fresh hope for better results.</p> Graphical Abstract <p></p>